After 70 years of development, Wuhan Grand Pharmaceutical Group Co., Ltd has grown into a medical joint venture with modernized scale with a registered capital of 85 million yuan, a site area of 300 mu, and a building area of 96, 000 square meters. The main products of the company are pharmaceutical preparations, pharmaceutical raw materials and intermediate products. With an annual sales income of 400 million yuan, annual foreign exchange 15 million yuan, and an annual production capacity of 200 million liquid preparations, more than 4 billion solid preparations, and over 4, 000 tons of pharmaceutical raw materials, it is a designated enterprise of the emergency medicines for the national war reserves and narcotics. Following the core values of �¢ï¿½ï¿½new products, new markets and new demand" and sticking to the development direction of �¢ï¿½ï¿½dual structure�¢ï¿½ï¿½ for raw materials and preparations, the company focuses on product development in such fields as cardiovascular, ophthalmology, liver-protective medicines, antibiotics and unique raw materials; with a professional scientific research team, the scientific research work has moved towards marketization and industrialization with an annual investment of more than 10 million yuan on the development of new products, and 3 types of the National Category �¢ï¿½�¡ New Drug and 9 types of the National Category �¢ï¿½�£ New Drug have been successively developed on a independent basis, and a number of new drugs are in registration. The company has now formed the antibacterial category with Enoxacin Gluconate Series at the core, the cardiovascular category with Tirofiban Hydrochloride and Sodium Chloride Injection at the core, the ophthalmic category with Ganciclovir Sodium for Injection and Pirenoxine Sodium eye drops at the core, and new and unique products to cure liver disease like Nuoning Series. Our products are sold to dozens of countries and regions like Asia, Europe and the United States and it is recognized as the key �¢ï¿½ï¿½Hi-Tech Enterprise�¢ï¿½ï¿½